GlobeNewswire·Apr 28, 2026, 8:00 AM ET

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio and Cellares announced a 10-year commercial agreement to supply rese-cel using Cellares' automated Cell Shuttle & future Cell Q platforms.
The partnership aims to enable flexible, scalable production of thousands of rese-cel batches annually with minimal capital investment.
The agreement targets per-batch manufacturing costs among the lowest in the industry for autologous cell therapy.
Cabaletta plans to submit a Biologics License Application (BLA) for rese-cel in myositis in 2027.
Initial translational data from the first two patients dosed with Cellares-manufactured rese-cel will be presented at the ASGCT conference in May 2026.
Longer-term clinical data for patients receiving Cellares-manufactured rese-cel is expected in the second half of 2026.
Cellares' automated platforms are designed to reduce labor requirements, improve scheduling lead times, & facilitate rapid global expansion.
Rese-cel is an investigational autologous CAR T cell therapy engineered with a fully human CD19 binder & 4-1BB co-stimulatory domain for autoimmune diseases.
The collaboration builds on an existing relationship between the companies that began in 2023 to automate & industrialize rese-cel manufacturing.
Cellares operates an IDMO Smart Factory network in the U.S., Netherlands, & Japan to support clinical & commercial cell therapy programs.